Navigation Links
CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant

- Tyrima Demonstrates Good Safety Profile and Excellent Pharmacokinetic Properties -

RESEARCH TRIANGLE PARK, N.C., March 13, 2007 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today announced top-line results from a Phase I clinical trial of Tyrima(TM), its lead candidate for the treatment of depression and anxiety. In this study, Tyrima was safe and well tolerated. Tyrima is a member of a novel class of drugs known as reversible inhibitors of monoamine oxidase A, or RIMAs.

The single-dose, placebo-controlled trial evaluated Tyrima in 41 subjects with doses escalating from 5 mg to 120 mg over the course of the study. Tyrima was well tolerated with no clinically significant adverse events even at the highest dose of 120 mg. Tyrima achieved high plasma concentrations that increased linearly with dose, and the favorable pharmacokinetic half-life should permit once or twice daily dosing. None of the safety and tolerability issues commonly associated with conventional monoamine oxidase A inhibitors (MAOIs) were seen in this study.

"The triple mechanism of MAOI antidepressants has the potential to provide enhanced efficacy to the 30% of patients who do not respond to current therapies, but use of these drugs has been limited by their propensity to cause serious side effects," said Dr. Atul Pande, chief medical officer of CeNeRx. "It is therefore encouraging that Tyrima, a selective and reversible MAO inhibitor specifically designed to avoid these side effects, demonstrated a promising safety profile in its first clinical trial, even at the highest dose. These results provide a strong foundation for proceeding to multiple dose safety studies."

Tyrima's unique mechanism elevates the levels of three key neurotransmitters (serotonin, norepinephrine and dopamine) that affect mood and anx
'"/>




Page: 1 2 3

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
6. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
7. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
8. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/14/2014)... 14, 2014  Celsion Corporation (NASDAQ: CLSN ), ... Company will ring the NASDAQ Stock Market closing bell on ... York, NY . President and CEO ... and EGEN management teams will participate in the closing bell ... live webcast will be available at https://new.livestream.com/nasdaq/live .  ...
(Date:7/14/2014)... SAN ANTONIO , July 14, 2014 /PRNewswire/ ... prodrug therapeutics for the treatment of cancer, announces ... S. Traube , has issued the following research ... Sheldon S. Traube , Director of Research, Kareg ... Read the full report: ...
(Date:7/14/2014)... , July 14, 2014 Synthetic ... technology partnership with global bioengineering leader DNA2.0, ... for quick-to-market products. The integration ... machine learning optimization technologies, such as ProteinGPS™ ... process of engineering proteins in the Pareto ...
Breaking Medicine Technology:Celsion Corporation to Ring the NASDAQ Stock Market Closing Bell on July 16, 2014 2Celsion Corporation to Ring the NASDAQ Stock Market Closing Bell on July 16, 2014 3Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 2Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 3Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 4Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 5Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 6Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 2Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 3
... attacks highlighted in new study ... global health outcomes meeting, ATHENS, Greece, Nov. 9 ... patients,prevention of recurrent heart attacks continues to be a major ... non-fatal heart,attack within the first three months of hospitalization for ...
... from an investigational,open-label, randomized study assessing extended ... anemia in subjects with Stages 3 - ... at the American Society,of Nephrology 41st Annual ... the FDA-approved,three-times-per-week (TIW) regimen, plus once-a-week (QW) ...
Cached Medicine Technology:Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death 2Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death 3Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death 4Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 2Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 3Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 4Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 5Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 6
(Date:7/14/2014)... The Encino cosmetic dentist at ... and porcelain veneers. These restorations are an excellent ... and greater loss of healthy tooth tissue. They work ... flaws on the tooth. Encino dentist Dr. Mastour and ... ensure they offer the most appropriate treatment recommendations for ...
(Date:7/14/2014)... HealthDay Reporter SUNDAY, July ... a faltering sense of smell might signal the early ... smell test could spot who needs more extensive screening ... ability to identify odors was associated with the loss ... "We,re trying to be able to diagnose Alzheimer,s ...
(Date:7/14/2014)... HealthDay Reporter MONDAY, July ... linked to multiple health issues, but dementia isn,t one of ... widowhood may even delay dementia, the researchers found. "For ... was associated with a later age of developing full-blown dementia ... Bryan Woodruff. Woodruff, an assistant professor of neurology ...
(Date:7/14/2014)... Connecticut (PRWEB) July 14, 2014 ... is celebrating its Grand Opening on Monday, July ... Connecticut 06830. The celebration will last all week ... all new patients. Everyone is welcomed to attend. ... M.D. who provides physician-administered skincare, anti-aging, weight loss ...
(Date:7/14/2014)... Huntington Beach, CA (PRWEB) July 14, 2014 ... of thousands of people undergo plastic surgery to reduce ... hit the market, however, eliminates the need to go ... mouth guard that works the jaw muscles, therefore tightening ... of having two chins. , Jawflex is used for ...
Breaking Medicine News(10 mins):Health News:Encino Esthetic Dental Group is Now Offering Lumineers and Porcelain Veneers 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 3Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 3Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2
... based on computerized simulation models suggests that the lifetime risk ... tomography (CT scan) coronary angiography varies widely, with the risk ... disease (CAD) is the leading cause of death in men ... 5 deaths, and a major cause of health care expenditures, ...
... reveals abnormal cells the woman will be offered colposcopy, ... cervix with a special microscope. Many women find the ... of anxiety before and during colposcopy. ,,Researchers ... trials that involved a total of 1441 women and ...
... The U.S. Food and Drug Administration (FDA) has approved the ... degenerative disc disease , one of the most common causes ... approved, the Prestige Cervical Disc, is manufactured by Medtronic Sofamor ... disc means that people with cervical degenerative disc disease now ...
... law to curb smoking to secure peoples' rights to the ... much committed towards implementing a comprehensive anti-tobacco law to reduce ... children and adolescents," Ali bin Shukur, Under-secretary of the Ministry ... ,A draft bill on smoking is being deliberated at ...
... of researchers have found that combining pre-operative chemotherapy and ... six percent when compared with surgery alone. ... the MRC Clinical Trials Unit in London after they ... from seven of these trials were available from trial ...
... a plan for coping with a pandemic flu outbreak, the ... disease outbreak and track its progress across the country. ... the borders if a pandemic flu outbreak occurs somewhere in ... president for biodefense:The reality is that there are tremendous challenges ...
Cached Medicine News:Health News:CT Scan Radiations may Lead to Cancer 2Health News:FDA Approves First Artificial Cervical Disc 2Health News:Chemotherapy Better for Non Small Cell Lung cancer 2Health News:Americas Preparations For Flu Outbreak Still Incomplete 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: